✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Liquid Biopsy Market Research Report Information By Biomarker Types (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Other Biomarker), By Application (Cancer Therapeutic Application, Reproductive Health, and Other Therapeutic), By Sample (Blood Sample, Urine Sample, and Other), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032


ID: MRFR/HC/0239-CR | 171 Pages | Author: Kinjoll Dey| February 2023

Liquid Biopsy Biomarker Market Segmentation


Liquid Biopsy Biomarker Types Outlook (USD Billion, 2018-2030)



  • Circulating Tumor Cells

  • Circulating Tumor DNA

  • Extracellular Vesicles

  • Others


Liquid Biopsy Biomarker Application Outlook (USD Billion, 2018-2030)



  • Cancer Therapeutic Application

  • Reproductive Health

  • Others


Liquid Biopsy Sample Outlook (USD Billion, 2018-2030)



  • Blood Sample

  • Urine Sample

  • Other


Liquid Biopsy Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)


    • North America Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • North America Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • North America Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • North America Liquid Biopsy by End User

      • Orthopedic Clinics

      • Multispecialty Hospitals

      • Neurology Clinics

      • Others




    • US Outlook (USD Billion, 2018-2030)


    • US Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • US Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • US Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • US Liquid Biopsy by End User

      • Orthopedic Clinics

      • Multispecialty Hospitals

      • Neurology Clinics

      • Others




    • CANADA Outlook (USD Billion, 2018-2030)


    • CANADA Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • CANADA Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • CANADA Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other






  • Europe Outlook (USD Billion, 2018-2030)


    • Europe Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Europe Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Europe Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Germany Outlook (USD Billion, 2018-2030)


    • Germany Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Germany Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others

      • Germany Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other



    • France Outlook (USD Billion, 2018-2030)


    • France Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • France Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • France Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • UK Outlook (USD Billion, 2018-2030)


    • UK Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • UK Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • UK Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • ITALY Outlook (USD Billion, 2018-2030)


    • ITALY Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • ITALY Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • ITALY Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • SPAIN Outlook (USD Billion, 2018-2030)


    • Spain Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Spain Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Spain Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Rest Of Europe Outlook (USD Billion, 2018-2030)


    • Rest Of Europe Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • REST OF EUROPE Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • REST OF EUROPE Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other






  • Asia-Pacific Outlook (USD Billion, 2018-2030)


    • Asia-Pacific Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Asia-Pacific Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Asia-Pacific Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • China Outlook (USD Billion, 2018-2030)


    • China Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • China Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • China Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Japan Outlook (USD Billion, 2018-2030)


    • Japan Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Japan Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Japan Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • India Outlook (USD Billion, 2018-2030)


    • India Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • India Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • India Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Australia Outlook (USD Billion, 2018-2030)


    • Australia Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Australia Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Australia Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)


    • Rest of Asia-Pacific Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Rest of Asia-Pacific Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Rest of Asia-Pacific Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other






  • Rest of the World Outlook (USD Billion, 2018-2030)


    • Rest of the World Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Rest of the World Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Rest of the World Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other








  • Middle East Outlook (USD Billion, 2018-2030)


    • Middle East Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Middle East Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Middle East Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Africa Outlook (USD Billion, 2018-2030)


    • Africa Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Africa Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Africa Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other




    • Latin America Outlook (USD Billion, 2018-2030)


    • Latin America Liquid Biopsy by Biomarker Types

      • Circulating Tumor Cells

      • Circulating Tumor DNA

      • Extracellular Vesicles

      • Others




    • Latin America Liquid Biopsy by Application

      • Cancer Therapeutic Application

      • Reproductive Health

      • Others




    • Latin America Liquid Biopsy by Sample

      • Blood Sample

      • Urine Sample

      • Other





Research Methodology on Liquid Biopsy Market


Introduction


The research methodology for the “Liquid Biopsy Market - Global Analysis and Forecasts” report is presented in this section. This research aims to provide in-depth insights into the global liquid biopsy market, by analyzing its current and projected performance concerning competitive market forces. This report provides an overview of the industry, market drivers and inhibitors influencing the market growth, competitive dynamics and key chapters of the market in terms of market segmentation and applications.


Research Approach


In order to collect information on market trends, drivers and inhibitors, the research process includes extrapolating the data and insights derived from second-party resources such as published reports, corporate websites, and public datasets. The prognosis of the global liquid biopsy market is established by balancing the vital qualitative and quantitative information which is obtained through primary interviews with Market Experts and Thought Leaders, as well as via extensive literature reviews including secondary sources such as directories, industry journals, white papers, technical papers, press releases, corporate annual reports from top players.


Moreover, market forecasts and projections are established by using advanced econometric techniques and models. The research process is divided into five sections – Primary & Secondary Exploration, Mapping of Market Opportunities, Market Assessments & Projections and Validation of Model Assumptions.


Scope of the Report


The report includes the landscape of the global liquid biopsy market, its size by value, by region and by end-user, competitive landscape and competitive strategies adopted by key players, market dynamics such as drivers, restraints, opportunities and challenges, new technological advancements and recent launches and future market trends. The notable market players included in the report comprise Genomic Health Inc., Life Technologies Corporation, Biocept Inc., Biodesix Inc., Cepheid, Cynvenio Biosystems Inc., Exosome Life Sciences, HTG, MDxHealth Ltd., Myriad Genetics Inc., and Trovagene Inc. In all, 17 company profiles have been included in the report.


Research Methodology


The research methodology for the liquid biopsy market is based on both primary and secondary research. For the primary research, a structured questionnaire is sent to industry experts, including key opinion leaders and thought leaders, who provided their insights and views on the market. In addition, macro- and micro-economic indicators of the industry are considered for arriving at the expected market growth during the forecast period. The secondary research is done using extensive research methodologies and in-depth analysis of published market reports and content from paid databases, journals and other third-party resources. The market data is also validated with proprietary analytics tools and models.


The market is segmented into product types, applications, end-users, geographies and key countries and stakeholders. Primary interviews are conducted to ascertain the market estimates and confirm the assumptions based on secondary and primary research. The report covers a geographic segmentation of the liquid biopsy market along with competitor analysis for key countries/regions such as North America (US, Canada, Mexico and the Rest of North America), Europe (The UK, Germany, France, Rest of Europe), Asia-Pacific (India, China, Japan, Rest of Asia Pacific) and Rest of the world (Middle East & Africa, Latin America).


Market Estimation


The global liquid biopsy market is estimated considering historical data and various market dynamics such as market drivers, opportunities and challenges. Thereafter, calculated values have been derived through an exhaustive triangulation method. All these factors are studied, analyzed, considered and weighted to arrive at the estimated values, which help to forecast the market position in terms of CAGR, size and other important parameters.


Data Sources


The data points considered to come up with the market estimates and forecasts include secondary research, databases and primary research (which includes interviews and surveys). The data points were aggregated and the resultant values were checked and validated using proprietary analytics models.


Customization


The report can be customized as per the requirements of the clients. Based on detailed analysis and insights into the market, customized deliveries on the research report are provided including company-specific analysis, regional-specific analysis and segment-specific analysis.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 Report Prologue

2 Introduction

2.1 Scope Of Study 16

2.2 Research Objective 16

2.3 Assumptions & Limitations 17

2.3.1 Assumptions 17

2.3.2 Limitations 17

2.4 Market Structure 17

3 Research Methodology

3.1 Research Process 18

3.2 Primary Research 19

3.3 Secondary Research 19

4 Market Dynamics

4.1 Introduction 20

4.2 Drivers 20

4.2.1 Comparatively Painless And Non-Invasive Technique 20

4.2.2 Early Real Time High Precision Detection Of Diseases 20

4.2.3 Useful For Designing Effective Treatment Strategies Based On The Real Time Molecular Assessment For The Progression Of The Disease 21

4.2.4 Rise In Cases Of Cancer And Other Diseases 21

4.2.5 Lifestyle Changes And Environmental Factors 21

4.2.6 Other Advantages Over Other Techniques 22

4.2.7 The Recent Technological Advancements Has Increased The Appeal Of Liquid Biopsy 22

4.2.8 Transferability Of Liquid Biopsy 22

4.2.9 Rising Investment In Research And Developments And Collaborations Between Companies And Public Organizations 23

4.2.10 Greater Focus On Venture Capital 23

4.2.11 Demographical Factors 23

4.3 Restraints 24

4.3.1 Prohibitive Costs Associated With Liquid Biopsy 24

4.3.2 Lower Sensitivity For Certain Biomarkers 24

4.3.3 Not All Cancers Patients Benefit From Early Detection 24

4.3.4 Liquid Biopsy Is Not All Non-Invasive 24

4.3.5 Differential Awareness And Availability Between Developing And Developed World 25

4.3.6 Issues In Venture Capital, Startups, And Collaborations 25

4.4 Opportunities 25

4.4.1 Growing Collaboration Between Companies Has Become The Entrance Gateway For New Firms 25

4.4.2 Funding From Public Organizations Is A Good Strategy To Reduce Developments Costs 26

4.4.3 Rise In Research And Developments Investment 26

4.4.4 Developing Economies Provide An Unserved Market For Liquid Biopsy 26

4.4.5 Growing Trend Of Start-Ups And Venture Investment In The Field Of Liquid Biopsy 26

4.5 Challenges 27

4.5.1 Information And Interest Gap Between The Investors And The Developers 27

4.5.2 Lack Of Trained Professionals In Developing Regions 27

4.5.3 Lack Of Standardization And Transparency 27

5 Market Factor Analysis

5.1 Porter’s Five Force Analysis 28

5.1.1 Bargaining Power Of Buyer 29

5.1.2 Bargaining Power Of Supplier 30

5.1.3 Threat From Substitutes 30

5.1.4 Threat From A New Entrant 30

5.1.5 Intensity Of Competitive Rivalry 31

5.2 Value Chain Analysis 32

5.2.1 Device Manufacturers 32

5.2.2 Software Developers 32

5.2.3 Reagent And Accessory Suppliers 32

5.2.4 Healthcare Providers 32

5.2.5 Patients 32

6 Liquid Biopsy Market, By Biomarker Types

6.1 Introduction 34

6.2 Circulating Tumor Cells (CTCs) 36

6.3 Circulating Tumour DNA (CtDNA) 37

6.4 Extracellular Vesicles (EVs) 39

6.5 Other Biomarker (Circulating RNA And Proteins) 40

7 Liquid Biopsy Market, By Application

7.1 Introduction 41

7.2 Cancer 43

7.3 Reproductive Health 44

7.4 Other Therapeutic Application 45

8 Global Liquid Biopsy Market, By Sample

8.1 Introduction 47

8.2 Blood Sample 49

8.3 Urine Sample 50

8.4 Other Sample 51

9 Global Liquid Biopsy Market By End User

9.1 Introduction 52

9.2 Hospitals And Laboratories 54

9.3 Academic And Research Centres 55

9.4 Other End Users 56

10 Global Liquid Biopsy Market, By Region

10.1 Introduction 57

10.2 North America 59

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.2.1 US

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.2.2 Canada 68

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3 Europe 72

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3.1 Germany 77

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3.2 France 81

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3.3 UK 85

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3.4 Italy 89

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3.5 Spain 93

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.3.6 Rest Of Europe 97

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4 Asia-Pacific 102

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4.1 Japan 107

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4.2 China 111

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4.3 India 115

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4.4 Australia 119

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4.5 South Korea 123

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.4.6 Rest Of Asia-Pacific 127

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.5 Middle East & Africa 132

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.5.1 UAE 137

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.5.2 Saudi Arabia 141

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.5.3 Egypt 145

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

10.5.4 Rest Of Middle East & Africa 149

Liquid Biopsy Market, By Biomarker Types

Liquid Biopsy Market, By Application

11 Company Profile

11.1 Guardant Health, Inc 154

11.1.1 Company Overview 154

11.1.2 Product/Business Segment Overview 154

11.1.3 Financial Overview 154

11.1.4 Key Developments 155

11.1.5 SWOT Analysis 156

11.2 Trovagene, Inc 157

11.2.1 Company Overview 157

11.2.2 Product/Business Segment Overview 157

11.2.3 Financial Overview 157

11.2.4 SWOT Analysis 158

11.3 RainDance Technologies, Inc. 159

11.3.1 Company Overview 159

11.3.2 Product/Business Segment Overview 159

11.3.3 Financial Overview 159

11.3.4 Key Developments 160

11.3.5 SWOT Analysis 160

11.4 Agena Bioscience Inc. Inc. 161

11.4.1 Company Overview 161

11.4.2 Product/Business Segment Overview 161

11.4.3 Financial Overview 161

11.4.4 Key Developments 161

11.4.5 SWOT Analysis 162

11.5 Admera Health 163

11.5.1 Company Overview 163

11.5.2 Product/Business Segment Overview 163

11.5.3 Financial Overview 163

11.5.4 Key Developments 163

11.5.5 SWOT Analysis 164

11.6 Biocept, Inc. 165

11.6.1 Company Overview 165

11.6.2 Product/Business Segment Overview 165

11.6.3 Financial Overview 165

11.6.4 Key Developments 165

11.7 Circulogene Theranostics 166

11.7.1 Company Overview 166

11.7.2 Product/Business Segment Overview 166

11.7.3 Financial Overview 166

11.7.4 Key Developments 166

11.8 Inivata Ltd 167

11.8.1 Company Overview 167

11.8.2 Product/Business Segment Overview 167

11.8.3 Financial Overview 167

11.8.4 Key Developments 167

11.9 SAGA Diagnostics AB 168

11.9.1 Company Overview 168

11.9.2 Product/Business Segment Overview 168

11.9.3 Financial Overview 168

11.9.4 Key Developments 168

11.10 Exosome Diagnostics 169

11.10.1 Company Overview 169

11.10.2 Product/Business Segment Overview 169

11.10.3 Financial Overview 169

11.10.4 Key Developments 169

12 List Of Tables

TABLE 1 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, USD MILLION (2022-2030 ) 34

TABLE 2 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2022-2030 (USD MILLION) 36

TABLE 3 CIRCULATING TUMOUR DNA (CTDNA) MARKET, BY REGION, 2022-2030 (USD MILLION) 38

TABLE 4 EXTRACELLULAR VESICLES (EVS) MARKET, BY REGION, 2022-2030 (USD MILLION) 39

TABLE 5 OTHER BIOMARKER TYPE MARKET, BY REGION, 2022-2030 (USD MILLION) 40

TABLE 6 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 42

TABLE 7 CANCER THERAPEUTIC APPLICATION MARKET, BY REGION, 2022-2030 (USD MILLION) 43

TABLE 8 REPRODUCTIVE HEALTH THERAPEUTIC APPLICATION MARKET, BY REGION, 2022-2030 ($ ILLION) 44

TABLE 9 OTHER THERAPEUTIC APPLICATION MARKET, BY REGION, 2022-2030 (USD MILLION) 45

TABLE 10 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE, 2022-2030 (USD MILLION) 47

TABLE 11 BLOOD SAMPLE MARKET, BY REGION, 2022-2030 (USD MILLION) 49

TABLE 12 URINE SAMPLE MARKET, BY REGION, 2022-2030 (USD MILLION) 50

TABLE 13 OTHER SAMPLE MARKET, BY REGION, 2022-2030 (USD MILLION) 51

TABLE 14 GLOBAL LIQUID BIOPSY MARKET BY END USER, 2022-2030 (USD MILLION) 52

TABLE 15 HOSPITALS AND LABORATORIES END USERS MARKET, BY REGION, 2022-2030 (USD MILLION) 54

TABLE 16 ACADEMIC AND RESEARCH CENTERS END USERS MARKET, BY REGION, 2022-2030 (USD MILLION) 55

TABLE 17 OTHER END USERS MARKET, BY REGION, 2022-2030 (USD MILLION) 56

TABLE 18 GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2022-2030 (USD MILLION) 57

TABLE 19 NORTH AMERICALIQUID BIOPSY MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 59

TABLE 20 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 60

TABLE 21 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 61

TABLE 22 NORTH AMERICA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 62

TABLE 23 NORTH AMERICA LIQUID BIOPSY MARKET BY END USERS 63

TABLE 24 U.S. LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 64

TABLE 25 U.S. LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 65

TABLE 26 U.S. LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 66

TABLE 27 U.S. LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 67

TABLE 28 CANADA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 68

TABLE 29 CANADA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 69

TABLE 30 CANADA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 70

TABLE 31 CANADA LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 71

TABLE 32 EUROPE LIQUID BIOPSY MARKET BY COUNTRY, 2022-2030 (USD MILLION) 72

TABLE 33 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 73

TABLE 34 EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 74

TABLE 35 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 75

TABLE 36 EUROPE LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 76

TABLE 37 GERMANY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 77

TABLE 38 GERMANY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 78

TABLE 39 GERMANY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 79

TABLE 40 GERMANY LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 80

TABLE 41 FRANCE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 81

TABLE 42 FRANCE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 82

TABLE 43 FRANCE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 83

TABLE 44 FRANCE LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 84

TABLE 45 UK LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 85

TABLE 46 UK LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 86

TABLE 47 UK LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 87

TABLE 48 UK LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 88

TABLE 49 ITALY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 89

TABLE 50 ITALY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 90

TABLE 51 ITALY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 91

TABLE 52 ITALY LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 92

TABLE 53 SPAIN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 93

TABLE 54 SPAIN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 94

TABLE 55 SPAIN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 95

TABLE 56 SPAIN LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 96

TABLE 57 REST OF EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 97

TABLE 58 REST OF EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 98

TABLE 59 REST OF EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 99

TABLE 60 REST OF EUROPE LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 100

TABLE 61 ASIA-PACIFIC LIQUID BIOPSY MARKET BY COUNTRY, 2022-2030 (USD MILLION) 102

TABLE 62 ASIA-PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 103

TABLE 63 ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 104

TABLE 64 ASIA-PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 105

TABLE 65 ASIA-PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 106

TABLE 66 JAPAN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 107

TABLE 67 JAPAN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 108

TABLE 68 JAPAN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 109

TABLE 69 JAPAN LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 110

TABLE 70 CHINA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 111

TABLE 71 CHINA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 112

TABLE 72 CHINA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 113

TABLE 73 CHINA LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 114

TABLE 74 INDIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 115

TABLE 75 INDIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 116

TABLE 76 INDIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 117

TABLE 77 INDIA LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 118

TABLE 78 AUSTRALIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 119

TABLE 79 AUSTRALIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 120

TABLE 80 AUSTRALIA LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 122

TABLE 81 REPUBLIC OF SOUTH KOREA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 123

TABLE 82 REPUBLIC OF SOUTH KOREA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 124

TABLE 83 REPUBLIC OF SOUTH KOREA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 125

TABLE 84 REPUBLIC OF SOUTH KOREA LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 126

TABLE 85 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 127

TABLE 86 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 128

TABLE 87 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 129

TABLE 88 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2022-2030 (USD MILLION) 130

TABLE 89 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY COUNTRY, 2022-2030 (USD MILLION) 132

TABLE 90 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 133

TABLE 91 MIDDLE EAST & AFRICA MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 134

TABLE 92 MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 135

TABLE 93 MIDDLE EAST & AFRICA MARKET BY END USERS, 2022-2030 (USD MILLION) 136

TABLE 94 UAE MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 137

TABLE 95 UAE MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 138

TABLE 96 UAE MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 139

TABLE 97 UAE MARKET BY END USERS, 2022-2030 (USD MILLION) 140

TABLE 98 SAUDI ARABIA MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 141

TABLE 99 SAUDI ARABIA MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 142

TABLE 100 SAUDI ARABIA MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 143

TABLE 101 SAUDI ARABIA MARKET BY END USERS, 2022-2030 (USD MILLION) 144

TABLE 102 EGYPT MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 145

TABLE 103 EGYPT MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 146

TABLE 104 EGYPT MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 147

TABLE 105 EGYPT MARKET BY END USERS, 2022-2030 (USD MILLION) 148

TABLE 106 REST OF MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 149

TABLE 107 REST OF MIDDLE EAST & AFRICA MARKET BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD MILLION) 150

TABLE 108 REST OF MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 151

TABLE 109 REST OF MIDDLE EAST & AFRICA MARKET BY END USERS, 2022-2030 (USD MILLION) 152

TABLE 110 GUARDANT HEALTH, INC: KEY DEVELOPMENTS 155

TABLE 111 TROVAGENE, INC CORPORATION: KEY DEVELOPMENTS 158

TABLE 112 RAINDANCE TECHNOLOGIES, INC. KEY DEVELOPMENTS 160

TABLE 113 AGENA BIOSCIENCE INC.: KEY DEVELOPMENTS 161

TABLE 114 ADMERA HEALTH: KEY DEVELOPMENTS 163

TABLE 115 BIOCEPT, INC.: KEY DEVELOPMENTS 165

TABLE 116 CIRCULOGENE THERANOSTICS: KEY DEVELOPMENTS 166

TABLE 117 INIVATA LTD: KEY DEVELOPMENTS 167

TABLE 118 TABLE 8: SAGA DIAGNOSTICS AB: KEY DEVELOPMENTS 168

TABLE 119 EXOSOME DIAGNOSTICSIS: KEY DEVELOPMENTS 169

13 List Of Figures

FIGURE 1 GLOBAL LIQUID BIOPSY: MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS OF MRFR 18

FIGURE 3 GLOBAL LIQUID BIOPSY: PORTER FIVE FORCES ANALYSIS 29

FIGURE 4 GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, MARKET SHARE 2022 (%) 35

FIGURE 5 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 USD MILLION 35

FIGURE 6 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2022, USD MILLION 37

FIGURE 7 CIRCULATING TUMOR DNA (CTDNA) MARKET, BY REGION, 2022, USD MILLION 38

FIGURE 8 EXTRACELLULAR VESICLES (EVS) MARKET, BY REGION, 2022 USD MILLION 39

FIGURE 9 OTHER BIOMARKER TYPE MARKET, BY REGION, 2022, (USD MILLION) 40

FIGURE 10 GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATIONS, MARKET SHARE 2022 (%) 42

FIGURE 11 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022, (USD MILLION) 43

FIGURE 12 CANCER THERAPEUTIC APPLICATION MARKET, BY REGION, 2022, (USD MILLION) 44

FIGURE 13 REPRODUCTIVE HEALTH THERAPEUTIC APPLICATION MARKET, BY REGION, 2022, (USD MILLION) 45

FIGURE 14 OTHER THERAPEUTIC APPLICATION MARKET, BY REGION, 2022, (USD MILLION) 46

FIGURE 15 GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE, MARKET SHARE 2022 (%) 48

FIGURE 16 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE, 2022, USD MILLION 48

FIGURE 17 BLOOD SAMPLE MARKET, BY REGION, 2022-2030 (USD MILLION) 49

FIGURE 18 URINE SAMPLE MARKET, BY REGION, 2022, USD MILLION 50

FIGURE 19 OTHER SAMPLE MARKET, BY REGION, 2022 (USD MILLION) 51

FIGURE 20 GLOBAL LIQUID BIOPSY MARKET, BY END USER, MARKET SHARE 2022 (%) 53

FIGURE 21 GLOBAL LIQUID BIOPSY MARKET BY END USER, 2022, USD MILLION 53

FIGURE 22 HOSPITALS AND LABORATORIES END USERS MARKET BY REGION, 2022, USD MILLION 54

FIGURE 23 ACADEMIC AND RESEARCH CENTERS END USERS MARKET, BY REGION, 2022, USD MILLION 55

FIGURE 24 OTHER END USERS MARKET, BY REGION, 2022, USD MILLION 56

FIGURE 25 GLOBAL LIQUID BIOPSY MARKET, BY REGION, MARKET SHARE 2022 (%) 58

FIGURE 26 GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2022-2030 (USD MILLION) 58

FIGURE 27 NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, MARKET SHARE 2022 (%) 59

FIGURE 28 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2022 (USD MILLION) 60

FIGURE 29 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 61

FIGURE 30 NORTH AMERICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022 (USD MILLION) 62

FIGURE 31 NORTH AMERICALIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 63

FIGURE 32 US LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 64

FIGURE 33 US LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 65

FIGURE 34 US LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 66

FIGURE 35 US LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 67

FIGURE 36 CANADA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 68

FIGURE 37 CANADA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 69

FIGURE 38 CANADA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 70

FIGURE 39 CANADA LIQUID BIOPSY MARKET BY END USERS, 2022, (USD MILLION) 71

FIGURE 40 EUROPE LIQUID BIOPSY MARKET BY COUNTRY, MARKET SHARE 2022 (%) 72

FIGURE 41 EUROPE LIQUID BIOPSY MARKET BY COUNTRY, 2022 (USD MILLION) 73

FIGURE 42 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 74

FIGURE 43 EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 75

FIGURE 44 EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 76

FIGURE 45 EUROPE LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 77

FIGURE 46 GERMANY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 78

FIGURE 47 GERMANY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 79

FIGURE 48 GERMANY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 80

FIGURE 49 GERMANY LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 81

FIGURE 50 FRANCE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 82

FIGURE 51 FRANCE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 83

FIGURE 52 FRANCE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 84

FIGURE 53 FRANCE LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 85

FIGURE 54 UK LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 86

FIGURE 55 UK LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 87

FIGURE 56 UK LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 88

FIGURE 57 UK LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 89

FIGURE 58 ITALY LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 90

FIGURE 59 ITALY LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 91

FIGURE 60 ITALY LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 92

FIGURE 61 ITALY LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 93

FIGURE 62 SPAIN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 94

FIGURE 63 SPAIN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 95

FIGURE 64 SPAIN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 96

FIGURE 65 SPAIN LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 97

FIGURE 66 REST OF EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 98

FIGURE 67 REST OF EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 99

FIGURE 68 REST OF EUROPE LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 100

FIGURE 69 REST OF EUROPE LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 101

FIGURE 70 ASIA-PACIFIC LIQUID BIOPSY MARKET BY COUNTRY, MARKET SHARE 2022 (%) 102

FIGURE 71 ASIA-PACIFIC LIQUID BIOPSY MARKET BY COUNTRY, 2022 (USD MILLION) 103

FIGURE 72 ASIA-PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 104

FIGURE 73 ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 105

FIGURE 74 ASIA-PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 106

FIGURE 75 ASIA-PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 107

FIGURE 76 JAPAN LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022-2030 (USD MILLION) 108

FIGURE 77 JAPAN LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 109

FIGURE 78 JAPAN LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 110

FIGURE 79 JAPAN LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 111

FIGURE 80 CHINA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 112

FIGURE 81 CHINA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 113

FIGURE 82 CHINA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 114

FIGURE 83 CHINA LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 115

FIGURE 84 INDIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 116

FIGURE 85 INDIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 117

FIGURE 86 INDIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 118

FIGURE 87 INDIA LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 119

FIGURE 88 AUSTRALIA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 120

FIGURE 89 AUSTRALIA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 121

FIGURE 90 AUSTRALIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022-2030 (USD MILLION) 121

FIGURE 91 AUSTRALIA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 122

FIGURE 92 AUSTRALIA LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 123

FIGURE 93 SOUTH KOREA LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 124

FIGURE 94 SOUTH KOREA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 125

FIGURE 95 SOUTH KOREA LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 126

FIGURE 96 SOUTH KOREA LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 127

FIGURE 97 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 128

FIGURE 98 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 129

FIGURE 99 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 130

FIGURE 100 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET BY END USERS, 2022 (USD MILLION) 131

FIGURE 101 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, MARKET SHARE BY COUNTRY, 2022 (%) 132

FIGURE 102 MIDDLE EAST & AFRICA MARKET BY COUNTRY, 2022 (USD MILLION) 133

FIGURE 103 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 134

FIGURE 104 MIDDLE EAST & AFRICA MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 135

FIGURE 105 MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 136

FIGURE 106 MIDDLE EAST & AFRICA MARKET BY END USERS, 2022 (USD MILLION) 137

FIGURE 107 UAE MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 138

FIGURE 108 UAE MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 139

FIGURE 109 UAE MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 140

FIGURE 110 UAE MARKET BY END USERS, 2022 (USD MILLION) 141

FIGURE 111 SAUDI ARABIA MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 142

FIGURE 112 SAUDI ARABIA MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 143

FIGURE 113 SAUDI ARABIA MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 144

FIGURE 114 SAUDI ARABIA MARKET BY END USERS, 2022 (USD MILLION) 145

FIGURE 115 EGYPT MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 146

FIGURE 116 EGYPT MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 147

FIGURE 117 EGYPT MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 148

FIGURE 118 EGYPT MARKET BY END USERS, 2022 (USD MILLION) 149

FIGURE 119 REST OF MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE, 2022 (USD MILLION) 150

FIGURE 120 REST OF MIDDLE EAST & AFRICA MARKET BY THERAPEUTIC APPLICATIONS, 2022 (USD MILLION) 151

FIGURE 121 REST OF MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE, 2022 (USD MILLION) 152

FIGURE 122 REST OF MIDDLE EAST & AFRICA MARKET BY END USERS, 2022 (USD MILLION) 153

FIGURE 123 GUARDANT HEALTH, INC: SWOT ANALYSIS 156

FIGURE 124 TROVAGENE, INC; RECENT FINANCIALS 157

FIGURE 125 TROVAGENE, INC CORPORATION: SWOT ANALYSIS 158

FIGURE 126 RAINDANCE: RECENT FINANCIAL 159

FIGURE 127 RAINDANCE TECHNOLOGIES: SWOT ANALYSIS 160

FIGURE 128 AGENA BIOSCIENCE INC.: SWOT ANALYSIS 162

FIGURE 129 ADMERA HEALTH: SWOT ANALYSIS 164

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Press Release
Category icon
Splendid Growth of Liquid Biopsy Market and the Game Changers
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)